VANI

Vivani Medical, Inc. (VANI) - Q1 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2025. Vivani Medical, Inc. is a clinical-stage biopharmaceutical company developing miniaturized, subdermal drug implants using its proprietary NanoPortal technology to address medication non-adherence in chronic diseases. The company operates two segments: the Biopharm Division (primary focus) and the Neurostimulation Division (Cortigent, Inc., a subsidiary targeted for spin-off). Vivani has no product revenue and relies on equity financing to fund operations.

Key Financial Metrics

Note: The company reported no revenue. Operating expenses increased slightly year-over-year. Cash balances decreased by approximately $5.3 million during the quarter.

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses increased by $0.33 million (5%) to $6.56 million. Research and Development (R&D) expenses rose by $0.49 million (13%) to $4.22 million, driven by the Biopharm division. General and Administrative (G&A) expenses decreased by $0.16 million (6%) to $2.34 million due to reduced professional services and personnel costs.
• Liquidity: Cash, cash equivalents, and restricted cash decreased from $19.69 million at the end of 2024 to $14.35 million at March 31, 2025. This decline was primarily due to operating cash burn of $5.16 million.
• Equity Transactions: In Q1 2025, the company issued 9,215 shares under its Sales Agreement with Jefferies, resulting in negative net proceeds of $28,000 due to issuance costs exceeding gross proceeds. This contrasts with Q1 2024, which included a registered direct offering yielding $13.7 million in net proceeds.

Guidance, Outlook, and Risks

• Clinical Milestones: The company successfully administered its first GLP-1 (exenatide) implant in the LIBERATE-1 clinical trial in March 2025 and achieved full enrollment in four weeks. Top-line results are expected in mid-2025.
• Strategic Shift: Vivani announced a change in strategy regarding its subsidiary, Cortigent. Efforts to pursue an IPO for Cortigent were discontinued in March 2025; the focus has shifted to filing a Form 10 to support a spin-off into an independent public company.
• Liquidity Outlook: Management estimates current cash will fund planned obligations for at least the next twelve months. However, the company expects to continue incurring operating losses and will require additional capital to continue operations.
• Recent Financing: Subsequent to the quarter end, the company entered into private sale transactions with entities affiliated with directors. A March 26, 2025 agreement provides for approximately $8.25 million in gross proceeds, and a May 12, 2025 agreement provides for approximately $3.0 million.
• Risks: Significant risks include the need for substantial additional financing, the uncertainty of clinical trial outcomes, and ongoing litigation with Pixium Vision SA regarding a terminated business combination (appeal proceedings are pending in France).

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $13 million cash balance against the projected burn rate of ~$5 million per quarter to confirm the "12-month" liquidity estimate.
• LIBERATE-1 Trial Data: Monitor the mid-2025 release of top-line data from the first-in-human trial, which is critical for future valuation and funding.
• Cortigent Spin-off: Track the progress of the Form 10 filing and the potential forgiveness of the intercompany loan between Vivani and Cortigent upon a successful spin-off.
• Private Placements: Confirm the closing and receipt of funds from the $8.25 million and $3.0 million private sale transactions with director-affiliated entities.
• Litigation Status: Review updates on the Pixium Vision SA litigation in the Paris Court of Appeal, noting the risk of the appeal lapsing if the judgment is not enforced or settled within two years.